Vosoritide
Also known as: Voxzogo, BMN 111
A C-type natriuretic peptide analog FDA-approved as Voxzogo to increase linear growth in children with achondroplasia. Prescription.
Last updated
Mechanism of Action
Vosoritide is a 39-amino-acid analog of C-type natriuretic peptide (CNP) modified to resist breakdown by neutral endopeptidase. It binds natriuretic peptide receptor B (NPR-B) on growth-plate chondrocytes, raising intracellular cGMP. This dampens the overactive FGFR3 signaling through the MAPK (RAF-1/MEK/ERK) pathway that causes achondroplasia, allowing more chondrocyte proliferation and endochondral bone growth.
- Half-life
- ~21-28 minutes
- Administration Routes
- Subcutaneous
- Research Status
- Clinical
Reported Benefits
- Increases annualized growth velocity in children with achondroplasia (phase 3)
- Growth gains sustained in multi-year extension studies
- Studied in infants and young children with achondroplasia
- Increased growth velocity in a phase 3 hypochondroplasia trial (2026)
Potential Side Effects
- Injection-site reactions (redness, swelling, bruising)
- Transient decreases in blood pressure, dizziness and fatigue
- Vomiting and nausea
- Arthralgia
Common Dosing
Labeled dosing is a weight-based subcutaneous injection once daily, given by a caregiver after training, with adequate food and fluid beforehand to reduce the risk of low blood pressure. Treatment continues only while growth plates remain open. Dosing is set and supervised by the prescribing clinician.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Closed epiphyses (no benefit once growth plates close)
- Significant cardiac disease or low blood pressure: use with caution
- Severe kidney impairment (not studied)
No documented stacking partners for Vosoritide yet.
- View
Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial
2020
- View
Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial
2024
- View
A Phase 3 Trial of Vosoritide in Children with Hypochondroplasia
2026